206 related articles for article (PubMed ID: 15711734)
21. Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53.
Besch R; Berking C; Kammerbauer C; Degitz K
Cell Death Differ; 2007 Apr; 14(4):818-29. PubMed ID: 17110957
[TBL] [Abstract][Full Text] [Related]
22. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.
Yebra M; Goretzki L; Pfeifer M; Mueller BM
Exp Cell Res; 1999 Jul; 250(1):231-40. PubMed ID: 10388537
[TBL] [Abstract][Full Text] [Related]
23. Vascular smooth muscle cells potentiate plasmin generation by both urokinase and tissue plasminogen activator-dependent mechanisms: evidence for a specific tissue-type plasminogen activator receptor on these cells.
Ellis V; Whawell SA
Blood; 1997 Sep; 90(6):2312-22. PubMed ID: 9310482
[TBL] [Abstract][Full Text] [Related]
24. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion.
Mazumdar A; Adam L; Boyd D; Kumar R
Cancer Res; 2001 Jan; 61(1):400-5. PubMed ID: 11196194
[TBL] [Abstract][Full Text] [Related]
25. [Expression of urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) plays a role in destruction of joint tissue in rapidly destructive coxarthropathy (RDC)].
Tamura N; Uzuki M; Matsumoto F; Rikimaru A; Kokubun S; Sawai T
Ryumachi; 2001 Oct; 41(5):851-7. PubMed ID: 11729663
[TBL] [Abstract][Full Text] [Related]
26. Evolving role of uPA/uPAR system in human cancers.
Dass K; Ahmad A; Azmi AS; Sarkar SH; Sarkar FH
Cancer Treat Rev; 2008 Apr; 34(2):122-36. PubMed ID: 18162327
[TBL] [Abstract][Full Text] [Related]
27. Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity.
Shi Z; Stack MS
Biochem J; 2007 Oct; 407(2):153-9. PubMed ID: 17880283
[TBL] [Abstract][Full Text] [Related]
28. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Albo D; Berger DH; Rothman VL; Tuszynski GP
J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
[TBL] [Abstract][Full Text] [Related]
29. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity.
Fazioli F; Resnati M; Sidenius N; Higashimoto Y; Appella E; Blasi F
EMBO J; 1997 Dec; 16(24):7279-86. PubMed ID: 9405357
[TBL] [Abstract][Full Text] [Related]
30. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
Fazioli F; Blasi F
Trends Pharmacol Sci; 1994 Jan; 15(1):25-9. PubMed ID: 8140655
[TBL] [Abstract][Full Text] [Related]
31. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
32. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
34. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
[TBL] [Abstract][Full Text] [Related]
35. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
36. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
Reinartz J; Link J; Todd RF; Kramer MD
Exp Cell Res; 1994 Oct; 214(2):486-98. PubMed ID: 7925643
[TBL] [Abstract][Full Text] [Related]
37. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
38. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies.
Rabbani SA; Xing RH
Int J Oncol; 1998 Apr; 12(4):911-20. PubMed ID: 9499455
[TBL] [Abstract][Full Text] [Related]
39. The urokinase receptor is required for human monocyte chemotaxis in vitro.
Gyetko MR; Todd RF; Wilkinson CC; Sitrin RG
J Clin Invest; 1994 Apr; 93(4):1380-7. PubMed ID: 8163642
[TBL] [Abstract][Full Text] [Related]
40. [Involvement of urokinase and its receptor in the remodeling of normal and pathological tissue].
Tkachuk VA; Stepanova VV; Volynskaia EA
Vestn Ross Akad Med Nauk; 1998; (8):36-41. PubMed ID: 9771129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]